challenges and opportunities in vaccines and global...
Post on 05-Mar-2021
1 Views
Preview:
TRANSCRIPT
Helen Evans, Deputy CEO
Challenges and Opportunities in Vaccines
and Global Immunisation
CSIS conference on the strategic power of vaccines Washington DC, 9 December 2011
Helen Evans – CSIS Conference
9 December 2011
Over 19 million children still unimmunised
Global number of under-five children unimmunised with 3 doses of DTP
Helen Evans – CSIS Conference
9 December 2011
Taking stock: the immunisation gap
136 million surviving newborns in 2010:
Source: Johns Hopkins Bloomberg School of Public Health;
UN,DESA, Population Division;
WHO/UNICEF
Helen Evans – CSIS Conference
9 December 2011
Synergies and shared learnings
Polio
eradication
Traditional
vaccines
Regional
vaccines
New
vaccines
Measles
elimination R&D: vaccine
improvements
R&D: future
vaccines
The immunisation landscape
Pneumococcal vaccine introductions:
introduced, approved and forecast
16
5
16
2 1
13 16
21
2 3
0
10
20
30
2009 2010 2011 2012 2013 2014 2015
number of
countries per
year
Forecast
Introduced
Approved
Pakistan
Madagascar
Ghana Uganda
Georgia
Moldova
Armenia Azerbaijan
Sudan
Zimbabwe Mozambique
Angola
Tanzania
Zambia
Niger Senegal
Bolivia
Sao Tome
Djibouti
Kiribati.
Gambia
Mali
Sierra Leone
Burundi
Benin
CAR Ethiopia
Guyana
Honduras
Nicaragua
Rwanda
Yemen
Kenya
Malawi
Cameroon Democratic
Republic of
the Congo
Helen Evans – CSIS Conference
9 December 2011
Rotavirus vaccine introductions: introduced,
approved and forecast
8 8
14
3 1 1
8
22
7 4
0
10
20
30
2009 2010 2011 2012 2013 2014 2015
Number
of
Countries
per year
Forecast
Introduced
Approved
Bolivia
Guyana
Nicaragua
Honduras Sudan
Tanzania
Madagascar
Angola
Republic of
the Congo
Cameroon Ghana
Niger
Yemen
Georgia Moldova
Armenia
Ethiopia
Djibouti
Malawi
Rwanda
Burundi
Source: Demand forecast v 4.0 Helen Evans – CSIS Conference
9 December 2011
Helen Evans – CSIS Conference
9 December 2011
Increased competition reduces vaccine price
Number of manufacturers and price decline of pentavalent vaccine
Source: UNICEF Supply Division, 2011
Helen Evans – CSIS Conference
9 December 2011
Increased competition reduces vaccine price
Number of manufacturers and volume of supply of pentavalent vaccine
Source: UNICEF Supply Division, 2011
Helen Evans – CSIS Conference
9 December 2011
Leveraging the market: GAVI’s Market Shaping in action 2011+
Short Term
Price decreases
• Pentavalent price decreases to $1.75 from $3 two years ago
• 67% price reduction offer on rotavirus - $2.5/dose
• 67% price reduction offer on HPV - $5/dose
Medium Term
New entrants
• 3 potential new entrants for rotavirus, yielding a further 40% price reduction target
• New entrants for pneumo, yielding a further price reduction of approx. 40%
• Graduating country price commitments
Long Term
Innovation
• Foster incremental innovation for appropriate and affordable new and follow-on products
• Improvements in vaccine technology
National leadership - Pneumococcal vaccine
launch, Kenya, 14 February 2011
Photo: GAVI/2011/Riccardo Gangale
Helen Evans – CSIS Conference
9 December 2011
Helen Evans – CSIS Conference
9 December 2011
Current cervical cancer mortality
Source: Globocan 2008, International Agency for Research on Cancer.
Courtesy of Progress in Cervical Cancer Prevention:
The CCA Report Card, August 2011
Helen Evans – CSIS Conference
9 December 2011
Introduction of HPV vaccine
Source: Courtesy of Progress in Cervical Cancer Prevention:
The CCA Report Card, August 2011
Status: July 2011
top related